Application: Cancer Immunotherapy Model
In vivo imaging of immune boosting using Immune Checkpoint Blocker (ICB) in breast cancer tissue
Abstract
This application examines the application of an immune checkpoint inhibitor targeting PD-1 in the 4T-1 xenograft animal model.
PD-1, present on the surface of T cells, binds to its ligand and prevents T cells from attacking cancer cells. Byblocking PD-1,
we aim to uncover the mechanisms of immune enhancement in immunotherapy within the tumor microenvironment.
Therapeutic Target(s)
ICB mixed cancer immunotherapy is related to the tumor microenvironment, which is composed of innate immune responses such as T cell activation,
focusing on boosting the immune response near cancer tissue. Drug Formulation
Mouse Model
Using the 4T-1 implanted xenograft mouse model, this study enhances the exploration of the tumor microenvironment in cancer immunotherapy,
emphasizing its relevance to immune activation.
Experiment Design
Group #1 – Anti-PD-1 only
- Dosing: Receive PD-1 inhibitor(10mg/kg) via intraperitoneal injection.
- Frequency: anti-PD-1 IP injection(Day1~3)
- Sample Size: N=3
Group #2 – Anti-PD-1 + Cancer Immunotherapy
- Dosing: Receive PD-1 inhibitor(10mg/kg, Day1~ 3) intraperitoneal injection with Cancer immunotherapy (Day1, 3) via intravenous injection.
- Frequency: anti-PD-1 IP injection(Day1~3)+ Cancer immunotherapy (Day1, 3)
- Sample Size: N=3